Charles W Drescher

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule
    Charles W Drescher
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M2 B230, Seattle, WA 98104, USA
    J Clin Oncol 31:387-92. 2013
  2. pmc Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening
    Charles W Drescher
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
    Cancer Prev Res (Phila) 5:1015-24. 2012
  3. ncbi request reprint Reported ovarian cancer screening among a population-based sample in Washington state
    C Drescher
    Department of Obstetrics Gynecology, University of Washington, Seattle 98104, USA
    Obstet Gynecol 96:70-4. 2000
  4. ncbi request reprint Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening
    Charles W Drescher
    Swedish Hospital and Medical Center, 1101 Madison Street, Suite 1500, Seattle, WA 98104, USA
    Cancer Epidemiol Biomarkers Prev 13:600-6. 2004
  5. pmc Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer
    M Robyn Andersen
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Gynecol Oncol 116:378-83. 2010
  6. pmc Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125
    Chirag A Shah
    University of Washington, Seattle, WA 98195, USA
    Cancer Epidemiol Biomarkers Prev 18:1365-72. 2009
  7. pmc Potential role of HE4 in multimodal screening for epithelial ovarian cancer
    Nicole Urban
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 103:1630-4. 2011
  8. pmc Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer
    Nicole Urban
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M2 B230, P O Box 19024, Seattle, WA 98109, USA
    Cancer Epidemiol Biomarkers Prev 21:2087-94. 2012
  9. pmc Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer
    Kimberly A Lowe
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 17:2480-7. 2008
  10. pmc An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription
    Emily C Knouf
    Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Nucleic Acids Res 40:499-510. 2012

Collaborators

Detail Information

Publications29

  1. pmc Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule
    Charles W Drescher
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M2 B230, Seattle, WA 98104, USA
    J Clin Oncol 31:387-92. 2013
    ..We demonstrated improvement in ovarian cancer early detection by using a longitudinal algorithm to monitor annual CA125 levels...
  2. pmc Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening
    Charles W Drescher
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
    Cancer Prev Res (Phila) 5:1015-24. 2012
    ..Identification of a first-line test that does substantially better than CA125 and has similar costs is required for screening to reduce ovarian mortality by at least 25% and be reasonably cost-effective...
  3. ncbi request reprint Reported ovarian cancer screening among a population-based sample in Washington state
    C Drescher
    Department of Obstetrics Gynecology, University of Washington, Seattle 98104, USA
    Obstet Gynecol 96:70-4. 2000
    ..To assess the prevalence of reported ovarian cancer screening among a population-based sample of women from Washington state and identify factors that influence the decision to be screened...
  4. ncbi request reprint Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening
    Charles W Drescher
    Swedish Hospital and Medical Center, 1101 Madison Street, Suite 1500, Seattle, WA 98104, USA
    Cancer Epidemiol Biomarkers Prev 13:600-6. 2004
    ....
  5. pmc Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer
    M Robyn Andersen
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Gynecol Oncol 116:378-83. 2010
    ..Prior studies suggest that combining the Symptom Index (SI) with a serum HE4 test or a CA125 test may improve prediction of ovarian cancer. However, these three tests have not been evaluated in combination...
  6. pmc Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125
    Chirag A Shah
    University of Washington, Seattle, WA 98195, USA
    Cancer Epidemiol Biomarkers Prev 18:1365-72. 2009
    ..To evaluate the effect of ovarian cancer risk on the performance of the serum biomarkers mesothelin, human epididymis protein 4 (HE4), and CA125...
  7. pmc Potential role of HE4 in multimodal screening for epithelial ovarian cancer
    Nicole Urban
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 103:1630-4. 2011
    ..03). Serum HE4 levels were found to increase with age and smoking status, suggesting that a longitudinal algorithm might improve its performance...
  8. pmc Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer
    Nicole Urban
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M2 B230, P O Box 19024, Seattle, WA 98109, USA
    Cancer Epidemiol Biomarkers Prev 21:2087-94. 2012
    ..Human epididymis protein 4 (HE4) is approved for clinical use with CA125 to predict epithelial ovarian cancer in women with a pelvic mass or in remission after chemotherapy. Previously reported reference ranges for HE4 are inconsistent...
  9. pmc Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer
    Kimberly A Lowe
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 17:2480-7. 2008
    ..To evaluate if serum levels of candidate ovarian cancer biomarkers vary with individual characteristics of healthy women who are likely candidates for an ovarian cancer screening program...
  10. pmc An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription
    Emily C Knouf
    Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Nucleic Acids Res 40:499-510. 2012
    ..This study delineates an integrative approach that can be applied to discover transcriptional regulatory mechanisms in other biological settings where analogous genomic data are available...
  11. pmc Bead-based ELISA for validation of ovarian cancer early detection markers
    Nathalie Scholler
    Translational Outcomes Research Laboratory, Fred Hutchinson Cancer Research Center, Public Health Sciences, and Harborview Medical Center, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 12:2117-24. 2006
    ....
  12. pmc Dangerous Combinations: Ingestible CAM Supplement Use During Chemotherapy in Patients with Ovarian Cancer
    M Robyn Andersen
    1 Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington
    J Altern Complement Med 19:714-20. 2013
    ..If risks associated with CAM use prove substantial, then improved systems to assure that all women get advice regarding supplement use during ovarian cancer treatment will be needed. ..
  13. ncbi request reprint Changes in cancer worry associated with participation in ovarian cancer screening
    M Robyn Andersen
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Psychooncology 16:814-20. 2007
    ..Further research will be required to examine the possibility that screening reduces worry when women receive only normal, presumably reassuring, results...
  14. doi request reprint Involvement in decision-making about treatment and ovarian cancer survivor quality of life
    M Robyn Andersen
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Gynecol Oncol 124:465-70. 2012
    ....
  15. doi request reprint Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases
    Pamela J Paley
    Pacific Gynecology Specialists Inc, Swedish Medical Center, Seattle, WA 98104, USA
    Am J Obstet Gynecol 204:551.e1-9. 2011
    ..We sought to examine outcomes in an expanding robotic surgery (RS) program...
  16. pmc Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries
    Stacia K Wyman
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 4:e5311. 2009
    ..A critical step toward these goals is to establish a comprehensive view of miRNAs expressed in epithelial ovarian cancer tissues as well as in normal ovarian surface epithelial cells...
  17. pmc Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition
    Ausra Bendoraite
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Gynecol Oncol 116:117-25. 2010
    ..Our objective was to characterize the expression and function of the miR-200 family of microRNAs (miRNA) in ovarian carcinogenesis...
  18. ncbi request reprint Development of an ovarian cancer symptom index: possibilities for earlier detection
    Barbara A Goff
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98196 6460, USA
    Cancer 109:221-7. 2007
    ..Currently, screening for ovarian cancer is not recommended for the general population. Targeting women with specific symptoms for screening has been evaluated only recently, because it was believed that symptoms had limited specificity...
  19. pmc Quality assessment and data analysis for microRNA expression arrays
    D Sarkar
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Nucleic Acids Res 37:e17. 2009
    ..We anticipate that the reagents and analytic approach presented here will be useful for improving the reliability of microRNA microarray experiments...
  20. ncbi request reprint Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer
    M R Andersen
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Gynecol Oncol 85:3-8. 2002
    ..jama 1995;273(6) 491-7]...
  21. pmc Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma
    M W McIntosh
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Gynecol Oncol 95:9-15. 2004
    ..e., they improve sensitivity), rule out false positives (i.e., improve specificity), or are able to detect the same cancers earlier...
  22. ncbi request reprint Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer
    Vivian Goodell
    Center for Translational Medicine in Women s Health, Tumor Vaccine Group, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Clin Oncol 24:762-8. 2006
    ..We questioned whether antibody immunity specific for ovarian cancer tumor antigens would predict disease outcome. We evaluated humoral immune responses against ovarian cancer antigens p53, HER-2/neu, and topoisomerase IIalpha...
  23. ncbi request reprint Clear cell adenocarcinoma of the vagina in a patient with vaginal endometriosis
    Chirag Shah
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Washington Medical Center, Box 356460, Seattle, WA 98195 6460, USA
    Gynecol Oncol 103:1130-2. 2006
    ..Malignant transformation of endometriosis is an infrequent complication of endometriosis. Extragonadal disease is uncommon...
  24. doi request reprint Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers
    Sheng Pan
    Department of Pathology, University of Washington, Seattle, Washington, USA
    OMICS 13:345-54. 2009
    ..Our results suggest that chemotherapy response may be determined by multiple and complex system properties involving extracellular-matrix, cell adhesion and junction proteins...
  25. ncbi request reprint Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels
    Jennifer J Stewart
    The Institute for Systems Biology, Seattle, Washington 98103, USA
    Mol Cell Proteomics 5:433-43. 2006
    ..Several proteins may be involved in modulating response to cisplatin and have potential as markers of treatment response or treatment targets...
  26. pmc Circulating microRNAs as stable blood-based markers for cancer detection
    Patrick S Mitchell
    Divisions of Human Biology, Clinical Research, and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 105:10513-8. 2008
    ..Our results establish the measurement of tumor-derived miRNAs in serum or plasma as an important approach for the blood-based detection of human cancer...
  27. pmc Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains
    Vitor M Faca
    Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 3:e2425. 2008
    ..We have characterized the cell surface proteome and the proteins released into the extra-cellular milieu of three ovarian cancer cell lines, CaOV3, OVCAR3 and ES2 and of ovarian tumor cells enriched from ascites fluid...
  28. ncbi request reprint Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer
    John V Brown
    Gynecologic Oncology Associates, Hoag Memorial Hospital Cancer Center, Newport Beach, CA 92663, USA
    Gynecol Oncol 88:136-40. 2003
    ..A 3-day regimen may be more convenient and less expensive than a 5-day schedule...
  29. pmc Systematic evaluation of candidate blood markers for detecting ovarian cancer
    Chana Palmer
    Canary Foundation, Scientific Programs, San Jose, California, United States of America
    PLoS ONE 3:e2633. 2008
    ..We evaluated the performance of a set of candidate blood markers and combinations of these markers in detecting serous ovarian cancer...